Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Besser, Michal J ^a,b   Shoham, Tsipi ^c   Harari Steinberg, Orit ^a   Zabari, Naama ^a,b   Ortenberg, Rona ^a,b   Yakirevitch, Arkadi ^a   Nagler, Arnon ^a   Loewenthal, Ron ^a   Schachter, Jacob ^a   Markel, Gal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GreenOnyx   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HLA C ANTIGEN;

ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CONTROLLED STUDY; EX VIVO STUDY; HLA MATCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; METASTATIC MELANOMA; NATURAL KILLER CELL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; GENOTYPING TECHNIQUES; HISTOCOMPATIBILITY TESTING; HLA-C ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM METASTASIS; RECEPTORS, KIR; TISSUE DONORS;

EID: 84874591531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057922     Document Type: Article

References (52)

1. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, et al. (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18: 151-158.
2. Hamerman JA, Ogasawara K, Lanier LL, (2005) NK cells in innate immunity. Curr Opin Immunol 17: 29-35.
3. Lanier LL, (2005) NK cell recognition. Annu Rev Immunol 23: 225-274.
4. Long EO, (1999) Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 17: 875-904.
5. Moretta A, Locatelli F, Moretta L, (2008) Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev 224: 58-69.
6. Moretta L, Moretta A, (2004) Killer immunoglobulin-like receptors. Curr Opin Immunol 16: 626-633.
7. Parham P, (2006) Taking license with natural killer cell maturation and repertoire development. Immunol Rev 214: 155-160.
8. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, et al. (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188: 953-960.
9. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, et al. (1999) NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 189: 787-796.
10. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, et al. (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190: 1505-1516.
11. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
12. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, et al. (1999) Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 96: 5640-5644.
13. Welte S, Kuttruff S, Waldhauer I, Steinle A, (2006) Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 7: 1334-1342.
14. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, et al. (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6: 515-523.
15. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, et al. (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409: 1055-1060.
16. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A, Lopez-Larrea C, (2008) NKG2D ligands: key targets of the immune response. Trends Immunol 29: 397-403.
17. van de Griend RJ, Bolhuis RL, Stoter G, Roozemond RC, (1987) Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol 138: 3137-3144.
18. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA, (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17: 6287-6297.
19. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, et al. (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339.
20. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
21. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, et al. (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110: 433-440.
22. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, et al. (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104: 170-177.
23. Frohn C, Doehn C, Durek C, Bohle A, Schlenke P, et al. (2000) Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J Immunother 23: 499-504.
24. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051-3057.
25. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, et al. (2009) Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS One 4: e5597.
26. Levy EM, Roberti MP, Mordoh J, (2011) Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011: 676198.
27. Leibson PJ, (1997) Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6: 655-661.
28. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, et al. (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity. 25: 331-342.
29. Clynes RA, Towers TL, Presta LG, Ravetch JV, (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446.
30. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796.
31. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, et al. (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-1129.
32. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, et al. (2010) Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother 59: 215-230.
33. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, et al. (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817.
34. Ledford H, (2011) Melanoma drug wins US approval. Nature 471: 561.
35. Flaherty KT, Yasothan U, Kirkpatrick P, (2011) Vemurafenib. Nat Rev Drug Discov 10: 811-812.
36. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
37. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
38. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
39. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, et al. (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16: 2646-2655.
40. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, et al. (2002) CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 168: 2803-2810.
41. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, et al. (2009) Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126: 186-200.
42. Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, et al. (2005) Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun 5: 3.
43. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, et al. (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31: 2680-2689.
44. Roda-Navarro P, Vales-Gomez M, Chisholm SE, Reyburn HT, (2006) Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc Natl Acad Sci U S A 103: 11258-11263.
45. S Hodi MS, Sznol M, McDermott DF, Carvajal RD, Lawrence DP, et al.(2012) Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL); 2012; Chicago, USA. J Clin Oncol 30: 15_suppl (May 20 Supplement), #8507.
46. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C,et al. (2012) Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med. 10.1056/NEJMoa1203421.
47. Rosenberg SA, (2012) Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 4: 127ps128.
48. Murphy WJ, Parham P, Miller JS, (2012) NK cells-from bench to clinic. Biol Blood Marrow Transplant 18: S2-7.
49. McKenna DH, Kadidlo DM, Cooley S, Miller JS, (2012) Clinical production and therapeutic applications of alloreactive natural killer cells. Methods Mol Biol 882: 491-507.
50. Weisdorf D, Cooley S, Devine S, Fehniger TA, Dipersio J, et al. (2012) T Cell-Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome. Biol Blood Marrow Transplant 18: 937-943.
51. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, et al. (2007) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110: 2561-2564.
52. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, et al. (2010) Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59: 1739-1744.